[go: up one dir, main page]

MX2017014998A - Uso de hidroxido de potasio en el tratamiento de la queratosis actinica. - Google Patents

Uso de hidroxido de potasio en el tratamiento de la queratosis actinica.

Info

Publication number
MX2017014998A
MX2017014998A MX2017014998A MX2017014998A MX2017014998A MX 2017014998 A MX2017014998 A MX 2017014998A MX 2017014998 A MX2017014998 A MX 2017014998A MX 2017014998 A MX2017014998 A MX 2017014998A MX 2017014998 A MX2017014998 A MX 2017014998A
Authority
MX
Mexico
Prior art keywords
potassium hydroxide
treatment
actinic keratosis
koh
keratosis
Prior art date
Application number
MX2017014998A
Other languages
English (en)
Other versions
MX385113B (es
Inventor
ZOELLER Philip
Wimmer Thomas
Giunta Alessandro
Wachall Bertil
Original Assignee
Infectopharm Arzneimittel Und Consilium Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectopharm Arzneimittel Und Consilium Gmbh filed Critical Infectopharm Arzneimittel Und Consilium Gmbh
Publication of MX2017014998A publication Critical patent/MX2017014998A/es
Publication of MX385113B publication Critical patent/MX385113B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al uso de hidróxido de potasio (KOH) en una forma (agente) farmacéuticamente aceptable, y a composiciones que comprenden respectivamente hidróxido de potasio (KOH), respectivamente, para el tratamiento dérmico de queratosis actínica.
MX2017014998A 2015-07-10 2015-07-10 Uso de hidróxido de potasio en el tratamiento de la queratosis actínica. MX385113B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2015/065840 WO2017008831A1 (en) 2015-07-10 2015-07-10 Use of potassium hydroxide in the treatment of actinic keratosis

Publications (2)

Publication Number Publication Date
MX2017014998A true MX2017014998A (es) 2018-03-23
MX385113B MX385113B (es) 2025-03-14

Family

ID=53716451

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014998A MX385113B (es) 2015-07-10 2015-07-10 Uso de hidróxido de potasio en el tratamiento de la queratosis actínica.

Country Status (19)

Country Link
US (1) US11045494B2 (es)
EP (1) EP3319637B1 (es)
JP (1) JP6659735B2 (es)
AU (1) AU2015402192B2 (es)
CA (1) CA2986295C (es)
DK (1) DK3319637T3 (es)
ES (1) ES2934131T3 (es)
FI (1) FI3319637T3 (es)
HR (1) HRP20221528T1 (es)
HU (1) HUE061201T2 (es)
IL (1) IL255291A0 (es)
MX (1) MX385113B (es)
NZ (1) NZ736342A (es)
PL (1) PL3319637T3 (es)
PT (1) PT3319637T (es)
RU (1) RU2706234C2 (es)
UA (1) UA122145C2 (es)
WO (1) WO2017008831A1 (es)
ZA (1) ZA201706946B (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5315404B2 (es) * 1973-12-29 1978-05-24
JPS5315404A (en) * 1976-07-29 1978-02-13 Hiromitsu Shimada Dermal resolvent and planing agent
US5084263A (en) * 1989-07-24 1992-01-28 Mccoy/Defalco Electrochemics, Inc. Method of preparing inorganic polymeric water complexes and products so produced
RU2146919C1 (ru) 1999-10-05 2000-03-27 Щербань Владимир Петрович Средство для удаления бородавок
WO2001024699A2 (en) 1999-10-06 2001-04-12 National Research Council Of Canada Non-invasive screening of skin diseases by visible/near-infrared spectroscopy
IE20000110A1 (en) * 2000-02-07 2001-08-22 Loctite R & D Ltd Applicator, Applicator Cap and a Container Having an Applicator Cap
RU2201236C2 (ru) 2001-06-01 2003-03-27 Щербань Владимир Петрович Средство для удаления доброкачественных новообразований на коже
ATE371458T1 (de) 2001-08-14 2007-09-15 Valderm Aps Behandlung von hyperproliferativen zuständen von körperoberflächen
US20030059450A1 (en) 2001-09-24 2003-03-27 Maibach Howard I. Method and topical formulation for treating skin conditions associated with aging
UA81222C2 (en) 2003-10-20 2007-12-25 Preparation for the removal of nonmalignant neoplasms on skin
WO2005065668A2 (en) * 2003-12-29 2005-07-21 Qlt Usa, Inc. Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
ATE468100T1 (de) 2006-10-13 2010-06-15 Evonik Goldschmidt Gmbh Hautbehandlungszusammensetzung
MX2009003981A (es) 2006-10-26 2009-04-27 Amgen Inc Agentes moduladores del receptor de calcio.
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
CN104940225A (zh) * 2009-08-24 2015-09-30 谭国梁 可使病变组织及病原体溶解消除的药物
US8652534B2 (en) 2009-10-14 2014-02-18 Berry Pharmaceuticals, LLC Compositions and methods for treatment of mammalian skin
UA56321U (ru) 2010-06-17 2011-01-10 Сергей Владимирович Селихов Средство гигиеническое для удаления новообразований кожных тканей
BR112014013227A2 (pt) 2011-11-30 2017-06-13 Merz Pharma Gmbh & Co Kgaa uso de álcoois peguilados no tratamento de queratose actínica
NZ606177A (en) 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
EP2860130B1 (de) * 2013-10-11 2016-01-06 Infectopharm Arzneimittel und Consilium GmbH Sicherheitsflasche

Also Published As

Publication number Publication date
AU2015402192A1 (en) 2017-11-02
UA122145C2 (uk) 2020-09-25
WO2017008831A1 (en) 2017-01-19
EP3319637A1 (en) 2018-05-16
DK3319637T3 (da) 2023-02-06
NZ736342A (en) 2020-05-29
IL255291A0 (en) 2017-12-31
RU2706234C2 (ru) 2019-11-15
CA2986295A1 (en) 2017-01-19
CA2986295C (en) 2023-01-03
US11045494B2 (en) 2021-06-29
ZA201706946B (en) 2019-02-27
PT3319637T (pt) 2022-12-27
US20180185409A1 (en) 2018-07-05
HUE061201T2 (hu) 2023-05-28
RU2017138375A3 (es) 2019-05-06
HRP20221528T1 (hr) 2023-02-17
JP2018519276A (ja) 2018-07-19
EP3319637B1 (en) 2022-11-09
RU2017138375A (ru) 2019-05-06
FI3319637T3 (fi) 2023-02-22
AU2015402192B2 (en) 2021-06-10
MX385113B (es) 2025-03-14
JP6659735B2 (ja) 2020-03-04
ES2934131T3 (es) 2023-02-17
PL3319637T3 (pl) 2023-03-20

Similar Documents

Publication Publication Date Title
CL2023001911A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
CL2016001547A1 (es) Composiciones para el cuidado oral
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
MX2017010272A (es) Composiciones para el cuidado bucal y metodos de uso.
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
PE20151759A1 (es) Imidazopiridazinas sustituidas
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
WO2014153009A3 (en) Thiosaccharide mucolytic agents
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
BR112013019924A8 (pt) Composições para cuidado oral
GT201300225A (es) Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
MX2019013251A (es) Una composicion nutricional para usarse para mejorar la atencion y/o reducir la impulsividad.